Rising finance costs
Finance costs are elevated due to debt-funded growth; management acknowledges the need to improve cost ratios.
FREDUNPHARMACEUTICALS / Q4-FY26 / risks
Keep the risk register visible.
Fredun Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Raw material price inflation
Geopolitical tensions have increased raw material costs; management mitigates with buffer stock but margins could be pressured if sustained.
Working capital strain from rapid growth
Fast organic growth may stretch working capital; management claims improvement but inventory remains high at ₹270 crore.